Table 2.
Demographical profiles and clinical variables at evaluation times in patients with ≥50%RR at F-UP1 and F-UP3 (i.e. long-lasting responders) compared with non-lasting responders
| F-UP1 ≥50%RR (n = 70) | F-UP1 no 50%RR (n = 84) |
p | FUP-3 ≥50%RR (n = 51) |
F-UP3 no %RR (n = 103) |
p | |
|---|---|---|---|---|---|---|
| Age years, mean (SD) | 49.1 (10.8) | 49.7 (11.4) | .746 | 47.7 (11.6) | 49.8 (11.0) | .298 |
| Sex % (n females) | 71.4 (50) | 75.3 (61) | 1.000 | 76.4 (39) | 69.9 (72) | .313 |
| BMI kg/m2, median (25th,75th) | 22.80 (20.85, 25.92) | 22.60 (21.00, 24.50) | .752 | 23.40 (21.30, 26.40) | 22.07 (20.93, 24.00) | .110 |
| CM % (n) | 67.1 (47) | 71.4 (60) | .595 | 74.5 (38) | 66.9 (69) | .438 |
| Baseline MO % (n) | 67.1 (47) | 66.7 (56) | 1.000 | 76.4 (39) | 62.1 (64) | .131 |
| Treatment % (n Erenumab) | 59.4(41) | 61.0 (50) | .489 | 50.9 (26) | 63.1 (65) | .195 |
| MMDs median (25th,75th) | ||||||
| Baseline | 16.0 (12.0,25.0) | 15.5 (12.8,20.0) | .928 | 15.0 (12.0,25.0) | 15.0 (11.0,22.5) | .545 |
| Last month | 4.0 (2.0,6.5) | 9.0 (5.0,14.0) | <.001 | 3.5 (2.0,7.0) | 6.0 (4.0,12.5) | <.001 |
| Last month RR median (25th,75th) | −77.3 (−85.4,-60.0) | −41.9 (−63.6,-21.1) | <.001 | −80.0 (− 86.7,-62.5) | −56.7 (−72.2,-31.7) | <.001 |
| MPI median (25th,75th) | ||||||
| Baseline | 18.0 (12.0,30.0) | 18.0 (13.0,29.3) | .912 | 18.0 (13.0,30.0) | 15.0 (12.0,30.0) | .594 |
| Last month | 4.0 (2.0,7.0) | 9.0 (5.0,13.0) | <.001 | 3.0 (1.0,6.0) | 8.0 (4.0,12.0) | <.001 |
| NRS median (25th,75th) | ||||||
| Baseline | 7.0 (6.0,8.0) | 7.0 (7.0,8.0) | .226 | 7.0 (6.0,8.0) | 7.0 (7.0,8.0) | .887 |
| Last month | 5.0 (3.0,6.0) | 6.0 (5.0,7.0) | <.001 | 4.0 (3.0,6.0) | 6.0 (5.0,7.0) | <.001 |
| HIT-6 median (25th,75th) | ||||||
| Baseline | 69.0 (64.0,72.5) | 66.0 (65.0,69.0) | .052 | 69.0 (64.0,73.0) | 66.0 (64.0,70.0) | .075 |
| Last month | 52.0 (39.0,59.0) | 58.0 (53.8,62.3) | .001 | 44.0 (38.0,54.0) | 57.0 (53.3,62.0) | <.001 |